PLYX

Polaryx Therapeutics Inc

Feb 20 • 04:00PM ET

2.61

-0.06 -2.25 %

Healthcare • Biotechnology • USA • NASD

Feb 18, 11:02 AMSell-the-news profit-taking erased yesterday's 77% surge on CRO selection for Phase 2 trial.

Index	-	P/E	-	EPS (ttm)	-0.17	Insider Own	91.33%	Shs Outstand	47.34M	Perf Week	-10.62%
Market Cap	123.56M	Forward P/E	-	EPS next Y	-	Insider Trans	0.01%	Shs Float	4.10M	Perf Month	-
Enterprise Value	117.81M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-8.21M	P/S	-	EPS this Y	-	Inst Trans	29.07%	Short Ratio	-	Perf Half Y	-
Sales	0.00M	P/B	23.31	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-92.54%
Book/sh	0.11	P/C	21.49	EPS next 5Y	-	ROE	-	52W High	48.91 -94.66%	Perf Year	-
Cash/sh	0.12	P/FCF	-	EPS past 3/5Y	- -	ROIC	-154.93%	52W Low	2.20 18.58%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	29.66% -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	6.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.77	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	8.77	EPS Q/Q	-85.28%	SMA20	-73.11%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-73.11%	Rel Volume	0.12	Prev Close	2.67
Employees	-	LT Debt/Eq	0.00	Earnings	-	SMA200	-73.11%	Avg Volume	4.53M	Price	2.61
IPO	Feb 02, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	564,746	Change	-2.25%

Feb-17-26 10:26AM	Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans (Benzinga) +64.32%
08:30AM	Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial (GlobeNewswire)
Feb-10-26 08:30AM	Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium (GlobeNewswire) -24.11%
Feb-05-26 08:30AM	Polaryx Therapeutics Welcomes New Members of the Board of Directors (GlobeNewswire) -28.89%
Feb-04-26 08:40AM	Polaryx to present late-breaker data related to Soteria ahead of trial (TipRanks)
08:30AM	Loading…
Feb-03-26 08:30AM	Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium as Company Prepares for SOTERIA Trial Launch (GlobeNewswire) -37.29%
Feb-02-26 08:30AM	Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol "PLYX" (GlobeNewswire)

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Landis G. Michael	Chief Financial Officer	Feb 18 '26	Buy	2.79	2,867	7,991	228,225	Feb 20 04:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLYX

Polaryx Therapeutics Inc

Upgrade your FINVIZ experience